MRI radiomics based on machine learning in high-grade gliomas as a promising tool for prediction of CD44 expression and overall survival.

Journal: Scientific reports
PMID:

Abstract

We aimed to predict CD44 expression and assess its prognostic significance in patients with high-grade gliomas (HGG) using non-invasive radiomics models based on machine learning. Enhanced magnetic resonance imaging, along with the corresponding gene expression and clinicopathological data, was downloaded from online database. Kaplan-Meier survival curves, univariate and multivariate COX analyses, and time-dependent receiver operating characteristic were used to assess the prognostic value of CD44. Following the screening of radiomic features using repeat least absolute shrinkage and selection operator, two radiomics models were constructed utilizing logistic regression and support vector machine for validation purposes. The results indicated that CD44 protein levels were higher in HGG compared to normal brain tissues, and CD44 expression emerged as an independent biomarker of diminished overall survival (OS) in patients with HGG. Moreover, two predictive models based on seven radiomic features were built to predict CD44 expression levels in HGG, achieving areas under the curves (AUC) of 0.809 and 0.806, respectively. Calibration and decision curve analysis validated the fitness of the models. Notably, patients with high radiomic scores presented worse OS (p < 0.001). In summary, our results indicated that the radiomics models effectively differentiate CD44 expression level and OS in patients with HGG.

Authors

  • Mingjun Yu
    Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
  • Jinliang Liu
    College of Information Engineering, Nanjing University of Finance and Economics, Nanjing, Jiangsu 210023, PR China; School of Automation, Southeast University, Nanjing, Jiangsu 210096, PR China. Electronic address: liujinliang@vip.163.com.
  • Wen Zhou
    Shanghai University, School of Computer Engineering and Science, Shanghai, China.
  • Xiao Gu
    Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China.
  • Shijia Yu
    Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. sjyu@cmu.edu.cn.